Adverse reactions to interleukin-17A and its receptor antagonists in the treatment of psoriasis

VernacularTitle:白细胞介素17A及其受体拮抗剂治疗银屑病的不良反应
Author: Ruojun WANG ; Ruoyu LI
From: Chinese Journal of Dermatology 2021;54(2):170-173
CountryChina
Language:Chinese
Abstract: Interleukin (IL) -17A plays a key role in the occurrence and development of psoriasis. To date, several marketed IL-17A and its receptor antagonists have been applied to the treatment of psoriasis, and definite therapeutic effects have been achieved. However, several adverse reactions, including upper respiratory tract infection, Candida infections, neutropenia, inflammatory bowel disease, which can be life-threatening, have been reported in clinical trials and after marketing of these biologics. This review summarizes clinical safety profiles of 3 types of interleukin-17A and its receptor antagonists, i.e., secukinumab, ixekizumab and brodalumab.